Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

INTRODUCTION: Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of migraine. The efficacy and safety of ubrogepant were demonstrated in two pivotal phase 3, single-attack, randomized, placebo-controlled trials (ACHIEVE I and AC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchinson, Susan, Dodick, David W., Treppendahl, Christina, Bennett, Nathan L., Yu, Sung Yun, Guo, Hua, Trugman, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140011/
https://www.ncbi.nlm.nih.gov/pubmed/33608814
http://dx.doi.org/10.1007/s40120-021-00234-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140011/
https://www.ncbi.nlm.nih.gov/pubmed/33608814
http://dx.doi.org/10.1007/s40120-021-00234-7

Ejemplares similares